| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CNCY.20080 |
| P953 | full work available at URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncy.20080 |
| https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncy.20080 | ||
| https://onlinelibrary.wiley.com/doi/full/10.1002/cncy.20080 | ||
| P698 | PubMed publication ID | 20731004 |
| P5875 | ResearchGate publication ID | 45801421 |
| P2093 | author name string | Nancy P. Caraway | |
| Ruth L. Katz | |||
| P2860 | cites work | Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test | Q94028781 |
| Follow-up in non-muscle invasive bladder cancer: facts and future | Q104582314 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer | Q30752503 | ||
| Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine | Q30985484 | ||
| The accuracy of urinary cytology in daily practice | Q33672302 | ||
| Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis | Q34785719 | ||
| Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications | Q34974222 | ||
| Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer | Q34978029 | ||
| Cytologic diagnosis of low-grade papillary urothelial neoplasms (low malignant potential and low-grade carcinoma) in the context of the 1998 WHO/ISUP classification | Q35097476 | ||
| The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement? | Q35192387 | ||
| Genetic instability and transitional cell carcinoma of the bladder | Q35608919 | ||
| The health economics of bladder cancer: a comprehensive review of the published literature. | Q35642541 | ||
| Urothelial cancer biomarkers for detection and surveillance | Q36418389 | ||
| Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer | Q36678640 | ||
| Fluorescence in situ hybridization: a multitarget approach in diagnosis and management of urothelial cancer | Q36691710 | ||
| Biomarkers for detection and surveillance of bladder cancer. | Q36808420 | ||
| Fluorescence in situ hybridization in diagnostic cytology | Q36886484 | ||
| Economic impact of tumor markers in bladder cancer surveillance | Q37074669 | ||
| Bladder cancer detection using FISH (UroVysion assay). | Q37250944 | ||
| Molecular pathogenesis and diagnostics of bladder cancer | Q37288841 | ||
| Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection | Q37288945 | ||
| Bladder cancer biomarkers and their role in surveillance and screening | Q37361497 | ||
| Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system | Q37670324 | ||
| "FISHing" to detect urinary and other cancers: validation of an imaging system to aid in interpretation | Q37680812 | ||
| Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology | Q38452177 | ||
| Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. | Q40166464 | ||
| The promising future of proteomics in cancer diagnosis and treatment | Q40415173 | ||
| A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals | Q42628824 | ||
| Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer | Q42789821 | ||
| uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. | Q50782051 | ||
| A side by side comparison of cytology and biomarkers for bladder cancer detection. | Q51631283 | ||
| Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. | Q51738268 | ||
| New developments in automated cytogenetic imaging: unattended scoring of dicentric chromosomes, micronuclei, single cell gel electrophoresis, and fluorescence signals. | Q52963345 | ||
| Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. | Q53628297 | ||
| Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder | Q57565348 | ||
| Relevance of Urine Telomerase in the Diagnosis of Bladder Cancer | Q59300443 | ||
| Natural history and treatment of low and high risk superficial bladder tumors | Q68260027 | ||
| Molecular detection of primary bladder cancer by microsatellite analysis | Q70923967 | ||
| Superficial bladder cancer: progression and recurrence | Q71108025 | ||
| Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms | Q71270881 | ||
| Diagnostic problems of urine cytology on initial follow-up after intravesical immunotherapy with Calmette-Guérin bacillus for superficial bladder cancer | Q72058188 | ||
| A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma | Q73062815 | ||
| Economic evaluation of NMP22 in the management of bladder cancer | Q73302963 | ||
| Low-grade urothelial carcinoma: reappraisal of the cytologic criteria on ThinPrep | Q73891979 | ||
| Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue | Q74326975 | ||
| NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer | Q74484687 | ||
| Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? | Q74581865 | ||
| Reliability of the routine cytological diagnosis in bladder cancer | Q74596043 | ||
| Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer | Q77214844 | ||
| A study comparing various noninvasive methods of detecting bladder cancer in urine | Q77711384 | ||
| Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat | Q77914296 | ||
| DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine | Q78647106 | ||
| UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer | Q79329213 | ||
| Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings | Q79517685 | ||
| Should we abandon the FISH test? | Q79673993 | ||
| ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma | Q80608577 | ||
| Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice | Q80772883 | ||
| Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer | Q80878135 | ||
| Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States | Q81170464 | ||
| Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice | Q81479508 | ||
| Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples | Q81637608 | ||
| Surveillance for recurrent bladder cancer using a point-of-care proteomic assay | Q82286136 | ||
| Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer | Q83216597 | ||
| Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays? | Q83318588 | ||
| The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy | Q83381017 | ||
| Reflex UroVysion testing in suspicious urine cytology cases | Q83612735 | ||
| Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria | Q83925403 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| fluorescence in situ hybridization | Q1336182 | ||
| diagnosis | Q16644043 | ||
| P304 | page(s) | 175-183 | |
| P577 | publication date | 2010-08-01 | |
| 2010-08-25 | |||
| P1433 | published in | Cancer Cytopathology | Q13452937 |
| P1476 | title | A review on the current state of urine cytology emphasizing the role of fluorescence in situ hybridization as an adjunct to diagnosis | |
| P478 | volume | 118 |
| Q84475759 | A multicolor fluorescence in situ hybridization assay: A monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: A prospective study |
| Q38063470 | A review of reporting systems and terminology for urine cytology |
| Q43981645 | Accuracy and risk of malignancy for diagnostic categories in urine cytology at a large tertiary institution. |
| Q35955528 | An ancillary method in urine cytology: Nucleolar/nuclear volume ratio for discrimination between benign and malignant urothelial cells |
| Q89661848 | An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer |
| Q46138162 | Ancillary techniques on direct-smear aspirate slides: a significant evolution for cytopathology techniques |
| Q40978472 | Association between chromosomal aberration of exfoliated bladder cells in the urine and oxidative stress in patients with bladder transitional cell carcinoma |
| Q47565259 | Clinical usefulness of urine cytology in the detection of bladder tumors in patients with neurogenic lower urinary tract dysfunction |
| Q84071745 | Coding changes in the United States front and center: implications for cytopathology |
| Q39037312 | Diagnostic dilemmas in patients with upper tract urothelial carcinoma |
| Q41839758 | Evaluation of a triple combination of cytokeratin 20, p53 and CD44 for improving detection of urothelial carcinoma in urine cytology specimens |
| Q33745140 | FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. |
| Q40295478 | Influence of hematuria and infection on diagnostic accuracy of urinary LASP1: a new biomarker for bladder carcinoma |
| Q30010143 | LASP-1, a novel urinary marker for detection of bladder cancer |
| Q41977489 | Paraganglioma of the urinary bladder with chromosome duplications detected by fluorescence in situ hybridization in urine exfoliated cells: A case report |
| Q47805656 | The combined application of urinary liquid-based cytology with fluorescence in situ hybridization and p16/Ki-67 dual immunostaining is valuable for improving the early diagnosis of upper tract urothelial carcinomas. |
| Q53136162 | The cytomorphological features of low-grade urothelial neoplasms vary by specimen type. |
| Q45139625 | Urine cytology - update 2013. A systematic review of recent literature |
| Q37895219 | Urine cytopathology: challenges, pitfalls, and mimics |
Search more.